Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluzoparib + Dalpiciclib in SNF3 HR+/HER2- Advanced Breast Cancer
NCT05759546Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Feb 2023
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of fluzoparib in Breast cancer (hormone receptor-positive/human epidermal growth factor receptor 2-negative), sponsored by Fudan University. Started Feb 2023; status: recruiting.
02
Drugs
fluzoparib
03
Conditions
Breast cancer (hormone receptor-positive/human epidermal growth factor receptor 2-negative)
Beyond the preview
Go deeper on NCT05759546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05759546.